Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib cream dose-ranging in Atopic Dermatitis
NCT03725722Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of delgocitinib in atopic dermatitis (AD) (5 arms), sponsored by LEO Pharma. Primary endpoint: Eczema Area and Severity Index at 8 weeks. Started Dec 2018; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03725722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725722.